Toll-like receptor 3 agonist complexed with cationic liposome augments vaccine-elicited antitumor immunity by enhancing TLR3-IRF3 signaling and type I interferons in dendritic cells

Vaccine

Volumn 30, Issue 32, 2012, Pages 4790-4799

  Wang, Ce ^a,b   Zhuang, Yan ^a   Zhang, Yijuan ^a   Luo, Zichao ^a   Gao, Ningning ^a   Li, Ping ^a   Pan, Hong ^a   Cai, Lintao ^a   Ma, Yifan ^a  

^a INSTITUTE OF GEOLOGY AND GEOPHYSICS   (China)

^b HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

Cancer vaccine; Cationic liposome; Cytotoxic T lymphocytes; Polyriboinosinic: polyribocytidylic acid; Toll like receptor 3; Type I IFN

Indexed keywords

1,2 DIOLEOYL 3 TRIMETHYLAMMONIOPROPANE; ALPHA INTERFERON; BETA INTERFERON; CANCER VACCINE; GAMMA INTERFERON; INTERFERON REGULATORY FACTOR 3; INTERLEUKIN 12P40; MESSENGER RNA; POLYCYTIDYLIC ACID; TOLL LIKE RECEPTOR 3; TUMOR ANTIGEN;

ADAPTIVE IMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER IMMUNIZATION; CANCER INHIBITION; CD8+ T LYMPHOCYTE; CELL LYSATE; CELL MATURATION; CELLULAR IMMUNITY; COMPLEX FORMATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RESPONSE; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG POTENTIATION; DRUG RECEPTOR BINDING; FEMALE; GENE EXPRESSION REGULATION; IMMUNOSTIMULATION; LIPOSOMAL DELIVERY; LIVER CELL CARCINOMA; MOUSE; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; TUMOR IMMUNITY; ZETA POTENTIAL;

ANIMALS; CANCER VACCINES; CATIONS; DENDRITIC CELLS; FATTY ACIDS, MONOUNSATURATED; FEMALE; INTERFERON REGULATORY FACTOR-3; INTERFERON TYPE I; KILLER CELLS, NATURAL; LIPOSOMES; LYMPHOCYTES, TUMOR-INFILTRATING; MICE; MICE, INBRED C57BL; NEOPLASMS, EXPERIMENTAL; POLYNUCLEOTIDES; QUATERNARY AMMONIUM COMPOUNDS; SIGNAL TRANSDUCTION; T-LYMPHOCYTES, CYTOTOXIC; TOLL-LIKE RECEPTOR 3;

EID: 84862549810     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.05.027     Document Type: Article

References (41)

1. Xiang S.D., Scalzo-Inguanti K., Minigo G., Park A., Hardy C.L., Plebanski M. Promising particle-based vaccines in cancer therapy. Expert Rev Vaccines 2008, 7(7):1103-1119.
2. + Th1 immunity with poly IC as adjuvant. J Exp Med 2009, 206(7):1589-1602.
3. Ma Y., Ross A.C. Toll-like receptor 3 ligand and retinoic acid enhance germinal center formation and increase the tetanus toxoid vaccine response. Clin Vaccine Immunol 2009, 16(10):1476-1484.
4. Durantez M., Fayolle C., Casares N., Belsue V., Riezu-Boj J.I., Sarobe P., et al. Tumor therapy in mice by using a tumor antigen linked to modulin peptides from Staphylococcus epidermidis. Vaccine 2010, 28(44):7146-7154.
5. + T cell immunity elicited by sequential daily immunization with exogenous antigen plus the TLR3 agonist poly(I:C). Vaccine 2011, 29(5):984-993.
6. + T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma. J Clin Oncol 2011, 29(3):330-336.
7. McCartney S., Vermi W., Gilfillan S., Cella M., Murphy T.L., Schreiber R.D., et al. Distinct and complementary functions of MDA5 and TLR3 in poly(I:C)-mediated activation of mouse NK cells. J Exp Med 2009, 206(13):2967-2976.
8. Sweeney S.E., Kimbler T.B., Firestein G.S. Synoviocyte innate immune responses: II. Pivotal role of IFN regulatory factor 3. J Immunol 2010, 184(12):7162-7168.
9. Wu C.Y., Yang H.Y., Monie A., Ma B., Tsai H.H., Wu T.C., et al. Intraperitoneal administration of poly(I:C) with polyethylenimine leads to significant antitumor immunity against murine ovarian tumors. Cancer Immunol Immunother 2011, 60(8):1085-1096.
10. Wischke C., Zimmermann J., Wessinger B., Schendler A., Borchert H.H., Peters J.H., et al. Poly(I:C) coated PLGA microparticles induce dendritic cell maturation. Int J Pharm 2009, 365(1-2):61-68.
11. Fujimura T., Nakagawa S., Ohtani T., Ito Y., Aiba S. Inhibitory effect of the polyinosinic-polycytidylic acid/cationic liposome on the progression of murine B16F10 melanoma. Eur J Immunol 2006, 36(12):3371-3380.
12. + T-cell responses by poly(I:C) incorporated into the CAF01 adjuvant via a double emulsion method. J Control Release 2011, 150(3):307-317.
13. Chen W., Yan W., Huang L. A simple but effective cancer vaccine consisting of an antigen and a cationic lipid. Cancer Immunol Immunother 2008, 57(4):517-530.
14. Lonez C., Vandenbranden M., Ruysschaert J.M. Cationic liposomal lipids: from gene carriers to cell signaling. Prog Lipid Res 2008, 47(5):340-347.
15. Ma Y., Zhuang Y., Xie X., Wang C., Zhou D., Wang F., et al. The role of surface charge density in cationic liposome-promoted dendritic cell maturation and vaccine-induced immune responses. Nanoscale 2011, 3(5):2307-2314.
16. Yoshikawa T., Okada N., Tsujino M., Gao J.Q., Hayashi A., Tsutsumi Y., et al. Vaccine efficacy of fusogenic liposomes containing tumor cell-lysate against murine B16BL6 melanoma. Biol Pharm Bull 2006, 29(1):100-104.
17. Niimi K., Koichiro A., Yoshiki S., Takeshi N., Misa W., Junko K., et al. TLR3-mediated synthesis and release of eotaxin-1/CCL11 from human bronchial smooth muscle cells stimulated with double-stranded RNA. J Immunol 2007, 178:489-495.
18. Zhang Y.J., Li Y.B., Ma Y.F., Liu S.H., Ye L.B. Dual effects of interleukin-18: inhibiting hepatitis B virus transcription and replication and inducing hepatoma cells migration. Am J Physiol: Gastrointest Liver Physiol 2011, 301:G565-G573.
19. Melief C.J., Van Der Burg S.H., Toes R.E., Ossendorp F., Offringa R. Effective therapeutic anticancer vaccines based on precision guiding of cytolytic T lymphocytes. Immunol Rev 2002, 188:177-182.
20. Perrot I., Deauvieau F., Massacrier C., Hughes N., Garrone P., Durand I., et al. TLR3 and rig-like receptor on myeloid dendritic cells and rig-like receptor on human NK cells are both mandatory for production of IFN- in response to double-stranded RNA. J Immunol 2010, 185:2080-2088.
21. Zaks K., Jordan M., Guth A., Sellins K., Kedl R., Izzo A., et al. Efficient immunization and cross-priming by vaccine adjuvants containing TLR3 or TLR9 agonists complexed to cationic liposomes. J Immunol 2006, 176(12):7335-7345.
22. Reimer T., Brcic M., Schweizer M., Jungi T.W. poly(I:C) and LPS induce distinct IRF3 and NF-kappaB signaling during type-I IFN and TNF responses in human macrophages. J Leukoc Biol 2008, 83(5):1249-1257.
23. Schaffert D., Kiss M., Rodl W., Shir A., Levitzki A., Ogris M., et al. Poly(I:C)-mediated tumor growth suppression in EGF-receptor overexpressing tumors using EGF-polyethylene glycol-linear polyethylenimine as carrier. Pharm Res 2011, 28(4):731-741.
24. Hirabayashi K., Yano J., Takesue H., Fujiwara N., Irimura T. Inhibition of metastatic carcinoma cell growth in livers by poly(I):poly(C)/cationic liposome complex (LIC). Oncol Res 1999, 11(11-12):497-504.
25. Peng S., Geng J., Sun R., Tian Z., Wei H. Polyinosinic-polycytidylic acid liposome induces human hepatoma cells apoptosis which correlates to the up-regulation of RIG-I like receptors. Cancer Sci 2009, 100(3):529-536.
26. Jasani B., Navabi H., Adams M. Ampligen: a potential toll-like 3 receptor adjuvant for immunotherapy of cancer. Vaccine 2009, 27(25-26):3401-3404.
27. Stojanovic A., Cerwenka A. Natural killer cells and solid tumors. J Innate Immun 2011, 3(4):355-364.
28. McCartney S., Vermi W., Gilfllan S., Cella M., Murphy T.L., Schreiber R.D., et al. Distinct and complementary functions of MDA5 and TLR3 in poly(I:C)-mediated activation of mouse NK cells. J Exp Med 2009, 206(13):2967-2976.
29. Lion E., Anguille Sb., Berneman Z.N., Smits E.L.J.M., Tendeloo V.F.I.V. Poly(I:C) enhances the susceptibility of leukemic cells to NK cell cytotoxicity and phagocytosis by DC. PLoS One 2011, 6(6):e20952.
30. Etienne M., Tschopp J. Toll-like receptors and RNA helicases: two parallel ways to trigger antiviral responses. Mol Cell 2006, 22(5):561-569.
31. Ebihara T., Azuma M., Oshiumi H., Kasamatsu J., Iwabuchi K., Matsumoto K., et al. Identification of a polyI:C-inducible membrane protein that participates in dendritic cell-mediated natural killer cell activation. J Exp Med 2010, 207(12):2675-2687.
32. Bourgeois C., Majer O., Frohner I.E., Lesiak-Markowicz I., Hildering K.-S., Glaser W., et al. Conventional dendritic cells mount a type I IFN response against Candida spp. requiring novel phagosomal TLR7-mediated IFN-b signaling. J Immunol 2011, 186:3104-3112.
33. Durand V., Wong S.Y., Tough D.F., Le Bon A. Shaping of adaptive immune responses to soluble proteins by TLR agonists: a role for IFN-alpha/beta. Immunol Cell Biol 2004, 82(6):596-602.
34. Diamond M.S., Kinder M., Matsushita H., Mashayekhi M., Dunn G.P., Archambault J.M., et al. Type I interferon is selectively required by dendritic cells for immune rejection of tumors. J Exp Med 2011, 208(10):1989-2003.
35. Gitlin L., Barchet W., Gilfillan S., Cella M., Beutler B., Flavell R.A., et al. Essential role of mda-5 in type I IFN responses to polyriboinosinic:polyribocytidylic acid and encephalomyocarditis picornavirus. Proc Natl Acad Sci USA 2006, 103(22):8459-8464.
36. Watanabe A., Tatematsu M., Saeki K., Shibata S., Shime H., Yoshimura A., et al. Raftlin is involved in the nucleocapture complex to induce poly(I:C)-mediated TLR3 activation. J Biol Chem 2012, 286(12):10702-10711.
37. Wong A.W., Scales S.J., Reilly D.E. DNA internalized via caveolae requires microtubule-dependent, Rab7-independent transport to the late endocytic pathway for delivery to the nucleus. J Biol Chem 2007, 282(31):22953-22963.
38. Nakamura T., Moriguchi R., Kogure K., Shastri N., Harashima H. Efficient MHC class I presentation by controlled intracellular trafficking of antigens in octaarginine-modified liposomes. Mol Ther 2008, 16(8):1507-1514.
39. Genin P., Lin R., Hiscott J., Civas A. Differential regulation of human interferon A gene expression by interferon regulatory factors 3 and 7. Mol Cell Biol 2009, 29(12):3435-3450.
40. Tailor P., Tamura T., Ozato K. IRF family proteins and type I interferon induction in dendritic cells. Cell Res 2006, 16(2):134-140.
41. Osterlund P., Veckman V., Siren J., Klucher K.M., Hiscott J., Matikainen S., et al. Gene expression and antiviral activity of alpha/beta interferons and interleukin-29 in virus-infected human myeloid dendritic cells. J Virol 2005, 79(15):9608-9617.